CSPC PHARMA (01093): CSPC Innovation Pharmaceutical's net profit attributable to shareholders for the first three quarters was RMB1.21 billion.
CSPC PHARMA (01093) announced that its subsidiary CSPC Innovation Pharmaceutical Co., Ltd. (CSPC Innovation) recorded operating revenue of RMB3.976 billion for the first three quarters of 2026, an increase of 149.62% year-on-year; net profit attributable to shareholders of the listed company was RMB1.21 billion; basic earnings per share were RMB0.8688.
CSPC PHARMA (01093) announced that its subsidiary CSPC Innovation Pharmaceutical Co., Ltd. (CSPC Innovation Pharmaceutical) recorded operating revenue of RMB3.976 billion for the first three quarters of 2026, an increase of 149.62% year-on-year; net profit attributable to shareholders of the listed company was RMB1.21 billion; basic earnings per share were RMB0.8688.
Related Articles
NAYUKI (02150) repurchased 940,000 shares on October 28 for HK$641,000.
.png)
SINOPEC SSC (01033) reported net profit attributable to shareholders of approximately RMB711 million for the first three quarters, up 6.2% year on year.
Biogen (BIIB.US) Q3 results beat expectations, with strong sales of rare disease drugs.
NAYUKI (02150) repurchased 940,000 shares on October 28 for HK$641,000.
SINOPEC SSC (01033) reported net profit attributable to shareholders of approximately RMB711 million for the first three quarters, up 6.2% year on year.
Biogen (BIIB.US) Q3 results beat expectations, with strong sales of rare disease drugs.
